Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 29

1.

Simplified Assessment of Antiretroviral Adherence and Prediction of Virological Efficacy in HIV-Infected Patients in Cambodia.

Segeral O, Madec Y, Ban B, Ouk V, Hak CR, Le Tiec C, Nerrienet E, Goujard C, Taburet AM, Delfraissy JF, Fontanet A.

AIDS Res Treat. 2010;2010:142076. doi: 10.1155/2010/142076. Epub 2009 Dec 31.

2.

Short communication: three years follow-up of first-line antiretroviral therapy in cambodia: negative impact of prior antiretroviral treatment.

Ségéral O, Limsreng S, Nouhin J, Hak C, Ngin S, De Lavaissière M, Goujard C, Taburet AM, Nerrienet E, Delfraissy JF, Ouk V, Dulioust A.

AIDS Res Hum Retroviruses. 2011 Jun;27(6):597-603. doi: 10.1089/AID.2010.0125. Epub 2011 Jan 17.

PMID:
21083413
3.

Treatment failure and mortality factors in patients receiving second-line HIV therapy in resource-limited countries.

Pujades-Rodríguez M, Balkan S, Arnould L, Brinkhof MA, Calmy A; AIDS Working Group of MSF.

JAMA. 2010 Jul 21;304(3):303-12. doi: 10.1001/jama.2010.980.

PMID:
20639564
4.

Effectiveness of boosted protease inhibitor-based regimens in HIV type 1-infected patients who experienced virological failure with NNRTI-based antiretroviral therapy in a resource-limited setting.

Siripassorn K, Manosuthi W, Chottanapund S, Pakdee A, Sabaitae S, Prasithsirikul W, Tunthanathip P, Ruxrungtham K; Bamrasnaradura Study Team.

AIDS Res Hum Retroviruses. 2010 Feb;26(2):139-48. doi: 10.1089/aid.2009.0125.

PMID:
20156097
5.

High rates of survival, immune reconstitution, and virologic suppression on second-line antiretroviral therapy in South Africa.

Fox MP, Ive P, Long L, Maskew M, Sanne I.

J Acquir Immune Defic Syndr. 2010 Apr 1;53(4):500-6. doi: 10.1097/QAI.0b013e3181bcdac1.

PMID:
19838128
6.

Three-year outcome data of second-line antiretroviral therapy in Ugandan adults: good virological response but high rate of toxicity.

Castelnuovo B, John L, Lutwama F, Ronald A, Spacek LA, Bates M, Kamya MR, Colebunders R.

J Int Assoc Physicians AIDS Care (Chic). 2009 Jan-Feb;8(1):52-9. doi: 10.1177/1545109708328538. Epub 2008 Dec 17.

PMID:
19095630
7.

Second-line antiretroviral therapy in resource-limited settings: the experience of Médecins Sans Frontières.

Pujades-Rodríguez M, O'Brien D, Humblet P, Calmy A.

AIDS. 2008 Jul 11;22(11):1305-12. doi: 10.1097/QAD.0b013e3282fa75b9.

PMID:
18580610
8.
9.

Impact of HIV-1 genetic diversity on plasma HIV-1 RNA Quantification: usefulness of the Agence Nationale de Recherches sur le SIDA second-generation long terminal repeat-based real-time reverse transcriptase polymerase chain reaction test.

Rouet F, Chaix ML, Nerrienet E, Ngo-Giang-Huong N, Plantier JC, Burgard M, Peeters M, Damond F, Ekouevi DK, Msellati P, Ferradini L, Rukobo S, Maréchal V, Schvachsa N, Wakrim L, Rafalimanana C, Rakotoambinina B, Viard JP, Seigneurin JM, Rouzioux C.

J Acquir Immune Defic Syndr. 2007 Aug 1;45(4):380-8.

PMID:
17468666
10.

Response to highly active antiretroviral therapy among severely immuno-compromised HIV-infected patients in Cambodia.

Madec Y, Laureillard D, Pinoges L, Fernandez M, Prak N, Ngeth C, Moeung S, Song S, Balkan S, Ferradini L, Quillet C, Fontanet A.

AIDS. 2007 Jan 30;21(3):351-9.

PMID:
17255742
11.

Drug resistance after failure of initial antiretroviral therapy in resource-limited countries.

Gallant JE.

Clin Infect Dis. 2007 Feb 1;44(3):453-5. Epub 2006 Dec 27. No abstract available.

PMID:
17205458
12.

Options for a second-line antiretroviral regimen for HIV type 1-infected patients whose initial regimen of a fixed-dose combination of stavudine, lamivudine, and nevirapine fails.

Sungkanuparph S, Manosuthi W, Kiertiburanakul S, Piyavong B, Chumpathat N, Chantratita W.

Clin Infect Dis. 2007 Feb 1;44(3):447-52. Epub 2006 Dec 27.

PMID:
17205457
13.

The WHO public-health approach to antiretroviral treatment against HIV in resource-limited settings.

Gilks CF, Crowley S, Ekpini R, Gove S, Perriens J, Souteyrand Y, Sutherland D, Vitoria M, Guerma T, De Cock K.

Lancet. 2006 Aug 5;368(9534):505-10.

PMID:
16890837
14.

Scaling up of highly active antiretroviral therapy in a rural district of Malawi: an effectiveness assessment.

Ferradini L, Jeannin A, Pinoges L, Izopet J, Odhiambo D, Mankhambo L, Karungi G, Szumilin E, Balandine S, Fedida G, Carrieri MP, Spire B, Ford N, Tassie JM, Guerin PJ, Brasher C.

Lancet. 2006 Apr 22;367(9519):1335-42.

PMID:
16631912
15.

Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study).

Castagna A, Danise A, Menzo S, Galli L, Gianotti N, Carini E, Boeri E, Galli A, Cernuschi M, Hasson H, Clementi M, Lazzarin A.

AIDS. 2006 Apr 4;20(6):795-803.

PMID:
16549962
16.

Cohort Profile: Antiretroviral Therapy in Lower Income Countries (ART-LINC): international collaboration of treatment cohorts.

Dabis F, Balestre E, Braitstein P, Miotti P, Brinkhof WG, Schneider M, Schechter M, Laurent C, Boulle A, Kabugo C, Capkun G, Seyler C, McIntyre J, Sprinz E, Bangsberg D, Van der Borght S, Egger M; Antiviral Therpapy in Lower Income Countries (ART-LINC) Study Group.

Int J Epidemiol. 2005 Oct;34(5):979-86. Epub 2005 Sep 12. No abstract available.

PMID:
16157617
17.

Efficacy of antiretroviral therapy programs in resource-poor settings: a meta-analysis of the published literature.

Ivers LC, Kendrick D, Doucette K.

Clin Infect Dis. 2005 Jul 15;41(2):217-24. Epub 2005 May 27.

PMID:
15983918
18.

Transfer and evaluation of an automated, low-cost real-time reverse transcription-PCR test for diagnosis and monitoring of human immunodeficiency virus type 1 infection in a West African resource-limited setting.

Rouet F, Ekouevi DK, Chaix ML, Burgard M, Inwoley A, Tony TD, Danel C, Anglaret X, Leroy V, Msellati P, Dabis F, Rouzioux C.

J Clin Microbiol. 2005 Jun;43(6):2709-17.

19.

Persistent antiretroviral activity of nucleoside analogues after prolonged zidovudine and lamivudine therapy as demonstrated by rapid loss of activity after discontinuation.

Eron JJ Jr, Bartlett JA, Santana JL, Bellos NC, Johnson J, Keller A, Kuritzkes DR, St Clair MH, Johnson VA.

J Acquir Immune Defic Syndr. 2004 Dec 15;37(5):1581-3.

PMID:
15577413
20.

Effectiveness and safety of a generic fixed-dose combination of nevirapine, stavudine, and lamivudine in HIV-1-infected adults in Cameroon: open-label multicentre trial.

Laurent C, Kouanfack C, Koulla-Shiro S, Nkoué N, Bourgeois A, Calmy A, Lactuock B, Nzeusseu V, Mougnutou R, Peytavin G, Liégeois F, Nerrienet E, Tardy M, Peeters M, Andrieux-Meyer I, Zekeng L, Kazatchkine M, Mpoudi-Ngolé E, Delaporte E.

Lancet. 2004 Jul 3-9;364(9428):29-34.

PMID:
15234853

Supplemental Content

Support Center